BASIC SCIENCE RESEARCH PROGRAM
Research projects are integrated under the following themes which are highly interactive and are beyond the conventional boundaries of a given expertise area and truly represent the CPDR paradigm:
- Translational CaP Genomics and Proteomics
- Novel CaP Cell Culture Models
- CaP Molecular Genetics
- Hormonal Mechanisms of CaP
Translational CaP Genomics and Proteomics
Translational research of cancer cell and molecular biology-derived discoveries in the pre-clinical or clinical research setting has been the priority of CPDR since its inception. A highly multi-disciplinary research environment of urologists, cancer cell and molecular biologists, genitourinary pathologists, bioinformatics and medical informatics experts, bio-statisticians, medical technologists and regulatory affairs experts supports the CPDR enterprise. Well-characterized CPDR biospecimens banks, recent discoveries showing consistent gene expression alterations in CaP and development of promising new molecular diagnostic technologies, have provided an optimal setting for CPDR to focus in the translational research areas, where we already have developed expertise or in the areas where new initiatives are needed.
Novel Cell Culture Models of CaP
The Prostate Cell Center was established in the newly-renovated CPDR laboratory at the Department of Surgery, USUHS, in January 2000 and has been very active over the years. The Prostate Cell Center has made major advances in the generation of short-term cultures from primary tumors of prostate cancer patients. (1) Total cell strains generated from primary tumors are 134, (2) the number of cell strains generated from normal tissue from the same patient are 72, (3) five well-characterized telomerase-immortalized human CaP cell lines from the tumor of African American and caucasian CaP patients. These cells are critical to the development and use of in vitro models and for the identification of novel therapeutic targets of prostate cancer.
CaP Molecular Genetics
Since its inception, CPDR-BRP has embraced the goal of defining CaP-specific genetic alterations that characterize the disease onset and/or progression. Genetic alterations that are "critical" in the genesis of CaP or molecular alterations that "consistently associate" with CaP will provide definitive molecular targets for the development of bio-markers and new therapeutic targets. This goal has become increasingly more apparent as most of the frequent gene alterations associated with other common human cancers such as breast cancer, colon cancer or lung cancer, do not seem to play a significant role in CaP.
Defining Androgen Signaling in CaP Onset and Progression
Androgen signaling is extremely important in the life and death of the prostate gland and is believed to play an important role in prostate cancer. Hormonal therapy, the most common treatment strategy for the treatment of metastatic prostate cancer works by inhibiting androgen signaling. Accumulating evidence suggests that alterations of androgen signaling in prostate cancer may involve structural or functional alterations of the critical genes at numerous points in the pathway.
Quarterly Guest Speakers
Dr. Lloyd Glover
Presentation: "A Urologist is Diagnosed with Prostate
Cancer -- Now What?"
Date: August 4, 2014
Time: 7-8:30 PM
Location: WRNMMC, America Building, 2nd floor, Room 2525
Contact: COL (ret) Jane Hudak for more information at 301-319-2918 or
or go to theWRNMMC UsToo! Newsletter Archive
Read the JULY 2016 CPDR E-Newsletter
May 28, 2016
Highlights at the 2016 AUA Annual Meeting in San Diego, Ca
The Center for Prostate Disease Research (CPDR) multi-disciplinary team - together with collaborators - presented 13 abstracts in moderated poster or podium presentations at the American Urological Association (AUA) Annual Meeting, May 6-10, 2016, San Diego, CA. The team was co-led by COL David McLeod, (Ret), MD, CPDR Director and Professor of the Department of Surgery, Uniformed Services University of the Health Sciences (USU) and the Walter Reed National Military Medical Center (WRNMMC); Dr. Shiv Srivastava, CPDR Co-Director and Professor in the Department of Surgery at USU and WRNMMC; COL Inger Rosner, MD, Associate Director, CPDR and Associate Professor, Department of Surgery, USU and the WRNNMC; Dr. Jennifer Cullen, Director of Epidemiology Research Program, CPDR and Research Assistant Professor, Department of Surgery, USU and WRNMMC and Dr. Albert Dobi, Associate Director, CPDR and Research Assistant Professor, Department of Surgery , USU and WRNMMC.
May 13, 2016
CPDR Student Participant Wins The AACR Gary J. Miller Undergraduate Prize for Cancer and Cancer Related Biomedical Research
A third place prize in the AACR Undergraduate Student Caucus and Poster Competition was awarded to Ms. Shahnoza Dusmatova, a CPDR participant in the DoD "Research and Education Program for Historically Black Colleges and Universities and Minority-Serving Institutions (HBCU/MI)".
May 2, 2016
CPDR Presentations and Highlights at the 2016 AACR Annual Meeting in New Orleans, La.
The Center for Prostate Disease Team has presented their new findings in prostate cancer research at the American Association for Cancer Research Annual Meeting 2016 in New Orleans, Louisiana, USA.
The Team led by Dr. David G. McLeod, Director and Dr. Shiv Srivastava, Co-Director presented the ground breaking discovery of the first recurrent cancer genomic defect of prostate cancers of African American men revealed by whole genome sequencing. The title of the poster presentation was “LSAMP gene deletion is associated with rapid disease progression in prostate cancer of African American men”.